XORTX Therapeutics (NASDAQ:XRTX) versus Vivos Therapeutics (NASDAQ:VVOS) Critical Comparison

Vivos Therapeutics (NASDAQ:VVOS) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vivos Therapeutics and XORTX Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
XORTX Therapeutics	1	0	0	0	1.00

Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 356.25%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than XORTX Therapeutics.

Volatility and Risk

Vivos Therapeutics has a beta of 6.1, suggesting that its share price is 510% more volatile than the S&P 500. Comparatively, XORTX Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vivos Therapeutics and XORTX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
XORTX Therapeutics	N/A	-150.01%	-106.53%

Valuation and Earnings

This table compares Vivos Therapeutics and XORTX Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57 million	0.44	-$21.17 million	($2.14)	-0.29
XORTX Therapeutics	N/A	N/A	-$2.66 million	($2.63)	-0.81

XORTX Therapeutics has lower revenue, but higher earnings than Vivos Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vivos Therapeutics beats XORTX Therapeutics on 9 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About XORTX Therapeutics

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.